Business
Further re Development Agreement
Further re Development Agreement.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \n \n RNS Number : 8571S\n Hemogenyx Pharmaceuticals PLC\n 13 July 2020\n \n \n \n \n Hemogenyx Pharmaceuticals plc \n \n \n \n \n \n (\"Hemogenyx Pharmaceuticals\" or the \"Company\")\n \n \n \n \n \n Further Re. Development Agreement\n \n \n \n \n \n On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company (\"GlobalCo\"). GlobalCo has now consented to the use of its name in the announcement, an updated version of which is shown below. \n \n \n \n \n \n \n \n \n Hemogenyx Pharmaceuticals plc \n \n \n \n \n \n (\"Hemogenyx Pharmaceuticals\" or the \"Company\")\n \n \n \n \n \n Development Agreement\n \n \n \n \n \n Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement (\"Agreement\") with Eli Lilly and Company (\"Lilly\"), a leading global pharmaceutical company engaged in the research, development, manufacture and marketing of human pharmaceutical and veterinary products.\n \n \n \n \n \n Under the Agreement, Lilly will supply the Company with certain biological materials and related confidential information in order for Company to perform research and development activities aimed at the discovery and validation of novel materials (\n \"\n Materials\n \"\n ) to be used for the treatment of systemic lupus erythematosus (\n \"\n Lupus\n \"\n ) and possibly other autoimmune diseases.\n \n \n \n \n \n This will complement the Company's own development work currently being undertaken. The Agreement stipulates certain confidential provisions.\n \n \n \n \n \n Under the Agreement, Hemogenyx Pharmaceuticals will grant Lilly a research license for anything jointly developed under the Agreement, as well as an option for an exclusive worldwide license to commercially exploit jointly developed Materials. If such option is not exercised by Lilly, the Company will have an option to license the jointly developed Materials itself.\n \n \n \n \n \n \n Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:\n \n \n \n \"\n \n \n This agreement provides additional support for our development plans for the development of novel treatments for Lupus and other autoimmune diseases, and complements the work that we are ...